Finasteride reduces serum PSA to a similar extent at 1 mg and 5 mg daily doses
This article has no abstract so we have provided the first paragraph of the full text.
Finasteride, a type 2 5
-reductase inhibitor, is used to treat benign prostatic hyperplasia (BPH) at 5 mg daily, and male-pattern alopecia at 1 mg daily. The 5 mg regimen reduces serum PSA levels, and guidelines currently recommend that PSA values of men who undergo prostate-cancer screening while taking 5 mg finasteride daily should be doubled—although this adjustment is only accurate in men who have taken 5 mg finasteride daily for 1–3 years, and a PSA increase of 0.3 ng/ml from nadir has been proposed as an alternative.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)